Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML?
(MedPage Today) -- For patients with chronic-phase chronic myeloid leukemia (CML), a response-based dose-reduction strategy for ponatinib (Iclusig) may limit its toxicity while maintaining or improving efficacy, a retrospective study suggested...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Hematology | Leukemia | Study | Toxicology